Must we Treat Uremic Dyslipidemia?

No abstract is available for this paper.

• Publication year

  1993

• Venue

  International Journal of Artificial Organs

• Publication date

  1993-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/039139889301600502PMID 8354581
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis.

  2009cited by this paper
• Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.

  2009cited by this paper
• Clinical pharmacokinetics of bezafibrate in patients with impaired renal function

  2004cited by this paper
• Is Atherogenesis Accelerated in Hemodialysis Patients

  1992influential reference
• Should there be a moratorium on the use of cholesterol lowering drugs?

  1992cited by this paper
• Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.

  1992cited by this paper
• Improved lipid profiles in patients undergoing high-flux hemodialysis.

  1992cited by this paper
• Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure.

  1992cited by this paper
• The uremic dyslipidemia: a cross-sectional and longitudinal study.

  1992cited by this paper
• Cholesterol-Lowering Effects oHypercholesterolemiain Patients With Mild to Moderate Hypercholesterolemia

  1992cited by this paper
• Doubts about preventing coronary heart disease.

  1992cited by this paper
• Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia.

  1992cited by this paper
• Cholesterol Reduction and Total Mortality

  1991cited by this paper
• The hypocholesterolemic effect of an antacid containing aluminum hydroxide.

  1991cited by this paper
• Might treatment of hypercholesterolaemia increase non-cardiac mortality?

  1991cited by this paper
• Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis.

  1991cited by this paper
• Hypertriglyceridemia as a vascular risk factor

  1991cited by this paper
• The hypertriglyceridemias: Risk and management. Epidemiology.

  1991cited by this paper
• Gemfibrozil-induced myopathy.

  1991cited by this paper
• Dietary reduction of serum cholesterol concentration: time to think again.

  1991cited by this paper
• Comparison of serial quantitative evaluation of calcified coronary artery plaque by ultrafast computed tomography in persons with and without obstructive coronary artery disease.

  1991cited by this paper
• Coronary heart disease: seven dietary factors.

  1991cited by this paper
• The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group.

  1991cited by this paper
• Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis.

  1991cited by this paper
• The hypertriglyceridemias: risk and management. Introduction.

  1991cited by this paper
• Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men.

  1991cited by this paper
• Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

  1990cited by this paper
• Lipid lowering drugs.

  1990cited by this paper
• Dialysis treatment in Australia, 1982 to 1988.

  1990cited by this paper
• Results of a long-term administration of omega-3 fatty acids in haemodialysis patients with dyslipoproteinaemia.

  1990cited by this paper
• Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.

  1990cited by this paper
• Management of hyperlipidemia of kidney disease.

  1990cited by this paper
• Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis.

  1990cited by this paper
• The Role of Cholesterol and Lipids in the Atherogenicity of Continuous Ambulatory Peritoneal Dialysis Patients Update 1990

  1990cited by this paper
• Mortality on dialysis--on the influence of early start, patient characteristics, and transplantation and acceptance rates.

  1990cited by this paper
• Causes, Consequences, and Treatment of Hyperlipidemia in Patients with Renal Disease

  1990cited by this paper
• Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.

  1990cited by this paper
• An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence.

  1990cited by this paper
• Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure.

  1990cited by this paper
• Effective hypolipidaemic therapy with beclobrate in haemodialysis patients: interference with L-carnitine.

  1990cited by this paper
• Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects.

  1990cited by this paper
• Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis.

  1989influential reference
• Are Lipid Abnormalities Reliable Cardiovascular Risk Factors in Dialysis Patients?

  1989cited by this paper
• Nicotinic acid-associated myopathy: a report of three cases.

  1989cited by this paper
• Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis.

  1989cited by this paper
• Hyperlipidaemia and Atherosclerosis in Chronic Dialysis Patients

  1989cited by this paper
• The status of hypertriglyceridemia as a risk factor for coronary heart disease.

  1989cited by this paper
• HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

  1988cited by this paper
• Lipoproteins and apolipoproteins during the progression of chronic renal disease.

  1988cited by this paper
• Lipoprotein abnormalities in chronic haemodialysis patients.

  1988cited by this paper
• Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration.

  1988cited by this paper
• Carnitine abnormalities in patients with renal insufficiency. Pathophysiological and therapeutical aspects.

  1988cited by this paper
• The effect of an antacid containing aluminium hydroxide on plasma cholesterol and lipoproteins

  1988cited by this paper
• Serum apolipoprotein profile of patients with chronic renal failure.

  1987cited by this paper
• Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure.

  1987cited by this paper
• Lipoprotein and Apolipoprotein Losses during Continuous Ambulatory Peritoneal Dialysis: ―腹膜透析排液中のリポ蛋白, アポ蛋白について―

  1987influential reference
• Carnitine metabolism in chronic renal failure.

  1987cited by this paper
• Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis.

  1987cited by this paper
• Carnitine metabolism in patients with chronic renal failure: effect of L-carnitine supplementation.

  1987cited by this paper
• Potential role of carnitine in patients with renal insufficiency

  1986cited by this paper
• Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: Pharmacokinetics and effects

  1986cited by this paper
• Fish oil modifies lipids and reduces platelet aggregability in haemodialysis patients.

  1986cited by this paper
• Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

  1986cited by this paper
• Serum free carnitine, carnitine esters and lipids in patients on peritoneal dialysis and hemodialysis.

  1986cited by this paper
• Endurance exercise training. An effective therapeutic modality for hemodialysis patients.

  1985cited by this paper
• Should hyperlipemia of renal failure be treated?

  1985cited by this paper
• Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients.

  1984cited by this paper
• Hyperlipidemia in renal failure: phenotypes and pathogenetic mechanisms.

  1984cited by this paper
• Dialysis-associated ischemic heart disease: insights from coronary angiography.

  1984cited by this paper
• The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.

  1984cited by this paper
• Therapy for uremic hyperlipidemia.

  1984cited by this paper
• Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias.

  1983cited by this paper
• Does atherosclerosis caused by dialysis limit this treatment?

  1983cited by this paper
• Accumulation of lipoprotein remnants in patients with chronic renal failure.

  1983cited by this paper
• Hyperlipidemia and Atherosclerosis in Chronic Dialysis Patients

  1983cited by this paper
• Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis.

  1983cited by this paper
• Treatment of uremic hypertriglyceridaemia with bezafibrate.

  1982cited by this paper
• Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study.

  1982cited by this paper
• Effects of a polyunsaturated fatty acid-rich diet on serum lipids in patients with chronic renal failure.

  1982cited by this paper
• What is the Evidence for Accelerated Atherogenesis in Uremia?

  1982cited by this paper
• The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins.

  1982cited by this paper
• Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease.

  1982cited by this paper
• Increased lipoprotein-remnant formation in chronic renal failure.

  1982cited by this paper
• Impaired lipoprotein lipase activation by uraemic and post-transplant sera.

  1981cited by this paper
• Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.

  1981cited by this paper
• Deranged fat metabolism and the lowering effect of carbohydrate-poor diet on serum triglycerides in patients with chronic renal failure.

  1980cited by this paper
• Atherosclerosis in dialysis and renal-transplant patients.

  1980cited by this paper
• An abnormal lipoprotein in the serum of uremic patients maintained on chronic hemodialysis.

  1980cited by this paper
• Metabolic effects of exercise training in hemodialysis patients.

  1980cited by this paper
• Clofibrate enhancement of mitochondrial carnitine transport system of rat liver and augmentation of liver carnitine and gamma-butyrobetaine hydroxylase activity by thyroxine.

  1980cited by this paper
• Drug treatment of hypertriglyceridaemia in chronic uraemic patients: preliminary report on D,L-carnitine and thiadenol.

  1980cited by this paper
• Long-term dietary treatment of hyperlipidaemia in patients treated with chronic haemodialysis.

  1980cited by this paper
• Dialysis hyperlipemia: response to dietary manipulations.

  1980cited by this paper
• Accelerated atherosclerosis in long-term dialysis and renal-transplant patients: fact or fiction?

  1980cited by this paper
• The role of hypertension in hemodialysis-associated atherosclerosis.

  1980cited by this paper
• Atherosclerosis in dialysis and renal-transplant patients.

  1980cited by this paper
• Vitamin B6 deficiency in maintenance dialysis patients: metabolic effects of repletion.

  1980cited by this paper
• Chronic clofibrate therapy in maintenance hemodialysis patients.

  1980cited by this paper
• Disposition pharmacokinetics of bezafibrate in man

  1979cited by this paper
• Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis.

  1979cited by this paper

• Severe hepatitis treated with an artificial liver support system

  2001cites this paper